Stéphanie Dulucq

2.2k total citations · 1 hit paper
55 papers, 900 citations indexed

About

Stéphanie Dulucq is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Stéphanie Dulucq has authored 55 papers receiving a total of 900 indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Hematology, 36 papers in Genetics and 11 papers in Rheumatology. Recurrent topics in Stéphanie Dulucq's work include Chronic Myeloid Leukemia Treatments (40 papers), Chronic Lymphocytic Leukemia Research (32 papers) and Eosinophilic Disorders and Syndromes (10 papers). Stéphanie Dulucq is often cited by papers focused on Chronic Myeloid Leukemia Treatments (40 papers), Chronic Lymphocytic Leukemia Research (32 papers) and Eosinophilic Disorders and Syndromes (10 papers). Stéphanie Dulucq collaborates with scholars based in France, Canada and Germany. Stéphanie Dulucq's co-authors include François‐Xavier Mahon, Maja Krajinović, Gabriel Étienne, Éric Lippert, Josy Reiffers, Béatrice Turcq, Stéphane Bouchet, Mathiéu Molimard, Albert Moghrabi and Delphine Réa and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Stéphanie Dulucq

47 papers receiving 882 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Characterization and Clinical Significance of Hemolysis After Pulsed Field Ablation for Atrial Fibrillation: Results of a Multicenter Analysis

2024 37 citations Miruna Popa, Sandrine Venier et al. Circulation Arrhythmia and Electrophysiology profile →

Peers

Countries citing papers authored by Stéphanie Dulucq

Since Specialization

Citations

This map shows the geographic impact of Stéphanie Dulucq's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphanie Dulucq with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphanie Dulucq more than expected).

Fields of papers citing papers by Stéphanie Dulucq

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphanie Dulucq. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphanie Dulucq. The network helps show where Stéphanie Dulucq may publish in the future.

Co-authorship network of co-authors of Stéphanie Dulucq

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphanie Dulucq. A scholar is included among the top collaborators of Stéphanie Dulucq based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphanie Dulucq. Stéphanie Dulucq is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient 2025 ·Annals of Hematology ·Grégoire Cullot, Valérie Lagarde, Jean-Michel Cayuela, Valérie Prouzet‐Mauleon, Béatrice Turcq, Yosr Hicheri, Lydia Roy, Thorsten Braun, Julien Mozziconacci, (unknown), Stéphanie Dulucq	0
2	Implementation science in hemato‐oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM) 2025 ·HemaSphere ·Jean‐Michel Cayuela, Pierre Sujobert, Pascale Flandrin‐Gresta, (unknown), (unknown), Damien Luque Paz, Cédric Pastoret, Stéphanie Dulucq, (unknown), (unknown), Isabelle Durand‐Zaleski, Olivier Kosmider, Elizabeth Macintyre	1
3	Characterization and Clinical Significance of Hemolysis After Pulsed Field Ablation for Atrial Fibrillation: Results of a Multicenter Analysis breakdown → 2024 ·Circulation Arrhythmia and Electrophysiology ·Miruna Popa, Sandrine Venier, Roberto Menè, Domenico G. Della Rocca, Frédéric Sacher, Nicolas Derval, Mélèze Hocini, Stéphanie Dulucq, Guido Caluori, Stéphane Combes, Jean‐Paul Albenque, (unknown), Bernhard Haller, Gian‐Battista Chierchia, Carlo de Asmundis, Pascal Defaye, Serge Bovéda, Pierre Jaı̈s	37
4	Beta‐thalassaemia intermedia due to a complex alpha‐globin rearrangement and a heterozygous beta thalassaemia mutation 2024 ·British Journal of Haematology ·(unknown), (unknown), (unknown), (unknown), (unknown), Arnaud Desclaux, (unknown), Stéphanie Dulucq, Julian Boutin	1
5	How to diagnose acid sphingomyelinase deficiency (ASMD) and Niemann–Pick disease type C from bone marrow and peripheral blood smears 2024 ·HemaSphere ·(unknown), Magali Pettazzoni, Roseline Froissart, Cécile Pagan, Thomas Boyer, Stéphanie Dulucq, (unknown), (unknown), Marie Loosveld, (unknown), Caroline Mayeur‐Rousse, Mélanie Pannetier, (unknown), (unknown), (unknown), Catherine Trichet, (unknown), (unknown)	0
6	Specific High-Sensitivity Enzymatic Reporter UnLOCKing-Mediated Detection of Oncogenic BCR::ABL1 and EGFR Rearrangements 2023 ·The CRISPR Journal ·Grégoire Cullot, Samuel Amintas, (unknown), Valérie Prouzet‐Mauleon, (unknown), (unknown), David Cappellen, Aurélie Bedel, François Moreau‐Gaudry, Stéphanie Dulucq, Sandrine Dabernat, Béatrice Turcq	3
7	Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐STIM study 2023 ·British Journal of Haematology ·Stéphanie Dulucq, Françoise Rigal‐Huguet, Franck E. Nicolini, Pascale Cony‐Makhoul, Martine Escoffre‐Barbe, Martine Gardembas, Laurence Legros, Philippe Rousselot, Jixing Liu, Delphine Réa, Véronique Mansat‐De Mas, Sandrine Hayette, Sophie Raynaud, (unknown), Fanny Robbesyn, (unknown), Stéphane Morisset, François‐Xavier Mahon, Gabriel Étienne	8
8	Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response 2021 ·Value in Health ·(unknown), Antoine Bénard, Pauline Bosco‐Lévy, Stéphanie Dulucq, (unknown), R. Lassalle, (unknown), François‐Xavier Mahon	3
9	Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line 2019 ·Annals of Hematology ·Stéphanie Dulucq, Gabriel Étienne, Stéphane Morisset, (unknown), Claudine Chollet, Fanny Robbesyn, Béatrice Turcq, Isabelle Tigaud, Sandrine Hayette, Franck E. Nicolini, François‐Xavier Mahon	1
10	Hemophagocytosis by blasts in acute lymphoblastic leukemia 2019 ·Blood Research ·(unknown), Coralie Derrieux, Stéphanie Dulucq	0
11	Accreditation strategy for rare somatic molecular abnormalities detected or quantified by polymerase chain reaction: GBMHM recommendations 2019 ·Annales de biologie clinique ·Pierre Sujobert, Stéphanie Dulucq, (unknown), Pascaline Etancelin, Anne Bouvier, (unknown), Aurélie Chauveau, Olivier Kosmider, Pascale Flandrin‐Gresta	1
12	The Evaluation of Residual Disease By Digital PCR, and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after for Stopping Imatinib First-Line in Chronic Phase CML Patients: Results of the STIM2 Study. 2018 ·Blood ·Franck E. Nicolini, Stéphanie Dulucq, Joëlle Guilhot, Gabriel Étienne, François‐Xavier Mahon	7
13	Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib 2018 ·Experimental Hematology ·Franck E. Nicolini, Vincent Alcazer, Pascale Cony‐Makhoul, Maël Heiblig, Stéphane Morisset, Gaëlle Fossard, Audrey Bidet, Anna Schmitt, Mohamad Sobh, Sandrine Hayette, François‐Xavier Mahon, Stéphanie Dulucq, Gabriel Étienne	6
14	Molecular Responses after Switching from a Standard-Dose Twice-Daily Nilotinib Regimen to a Reduced-Dose Once-Daily Schedule in Patients with Chronic Myeloid Leukemia: A Real Life Observational Study (NILO-RED) 2017 ·Blood ·Delphine Réa, Jean‐Michel Cayuela, Stéphanie Dulucq, Gabriel Étienne	24
15	A novel method for room temperature distribution and conservation of RNA and DNA reference materials for guaranteeing performance of molecular diagnostics in onco-hematology: A GBMHM study 2015 ·Clinical Biochemistry ·Jean‐Michel Cayuela, (unknown), (unknown), Olivier Nibourel, Stéphanie Dulucq, Éric Delabesse, Patrick Villarèse, Sandrine Hayette, Julien Mozziconacci, Elizabeth Macintyre	4
16	Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy 2013 ·Haematologica ·Gabriel Étienne, Stéphanie Dulucq, Franck E. Nicolini, Stéphane Morisset, Marylise Fort, Anna Schmitt, M C Etienne, Sandrine Hayette, Éric Lippert, (unknown), Isabelle Tigaud, (unknown), Gérald Marit, Josy Reiffers, François Xavier Mahon	40
17	Performance of Rapid Diagnostic Tests for Imported Malaria in Clinical Practice: Results of a National Multicenter Study 2013 ·PLoS ONE ·Sandrine Houzé, Isabelle Boutron, (unknown), Marie Dalichampt, Christophe Choquet, I. Poîlane, N. Godineau, Anne‐Sophie Le Guern, Marc Théllier, (unknown), Odile Fenneteau, Pascal Millet, Stéphanie Dulucq, Véronique Hubert, Pascal Houzé, Florence Tubach, Jacques Le Bras, Sophie Matheron	20
18	Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells 2011 ·Blood ·Romain Gioia, Cédric Leroy, Claire Drullion, Valérie Lagarde, Gabriel Étienne, Stéphanie Dulucq, Éric Lippert, Serge Roche, François‐Xavier Mahon, Jean‐Max Pasquet	75
19	Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience 2011 ·Haematologica ·Sophie de Guibert, Régis Peffault de Latour, Nathalie Varoqueaux, Hélène Labussière, Bernard Rio, (unknown), Jean‐Richard Eveillard, Stéphanie Dulucq, Anne Marie Stoppa, Didier Bouscary, François Girodon, Bernard Bonnotte, (unknown), Gèrard Socié, Thierry Lamy	35
20	The pharmacogenetics of imanitib 2010 ·Genome Medicine ·Stéphanie Dulucq, Maja Krajinović	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact